Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133436 | 0.83 | GAA (0.50) | PDE3BPDE3AGSK3BNPY5RALDH1A1 | |
| SCHEMBL2130711 | 0.80 | MAPK1 (0.53) | PDE3BPDE3ANPY5RALDH1A1MAPT | |
| SCHEMBL3462531 | 0.80 | XDH (0.42) | XDH | |
| SCHEMBL28133332 | 0.80 | PDE3B (0.53) | PDE3BPDE3AGSK3BALDH1A1MAPT | |
| SCHEMBL30062507 | 0.77 | IDO1 (0.44) | MAPTXDHIDO1 | |
| SCHEMBL27880566 | 0.77 | CDK5 (0.41) | GSK3BALDH1A1 | |
| SCHEMBL30060621 | 0.77 | KMT2A (0.58) | NPY5RALDH1A1MAPTHPGDHPGDS | |
| SCHEMBL6294683 | 0.77 | KMT2A (0.58) | NPY5RALDH1A1MAPTHPGDHPGDS | |
| SCHEMBL12071739 | 0.75 | GCK (0.43) | PDE3BPDE3AMAPTGAAXDH | |
| SCHEMBL5502035 | 0.75 | CDC7 (0.40) | PDE3BPDE3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1115721-A1 | PYRIMIDONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018758-A1 | PYRIMIDONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-04-06 | — | — | WO | claimed |
| US-11987560-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| CN-110036006-B | Preparation and use of pyrimidinone derivatives | 癌症研究科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| US-20220153706-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-10960005-B2 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10849898-B2 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200297727-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10654810-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200113905-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10548896-B2 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10023543-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170349556-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | QUANTIEL PHARMACEUTICALS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170349555-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-9776974-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170114024-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | QUANTIEL PHARMACEUTICALS, INC. | 2017-04-27 | — | — | US | disclosed |
| US-9573930-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160152595-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160130247-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | QUANTIEL PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20150315187-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548896-B2 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | KDM1A, KDM1B, NSD1 | PDE3B 4126/4885PDE3A 3839/4885GSK3B 2241/4885 |
| US-10960005-B2 | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas | KDM1A, KDM1B, NSD1 | PDE3B 4126/4885PDE3A 3839/4885GSK3B 2241/4885 |
| US-20200113905-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | KDM1A, KDM1B, NSD1 | PDE3B 4126/4885PDE3A 3839/4885GSK3B 2241/4885 |
| US-11987560-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-10849898-B2 | Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas | KDM1A, KDM1B, NSD1 | PDE3B 4126/4885PDE3A 3839/4885GSK3B 2241/4885 |
| US-20170114024-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-20150315187-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-20170349556-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-10654810-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-20220153706-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-20170349555-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-20200297727-A1 | TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS | KDM1A, KDM1B, NSD1 | PDE3B 4126/4885PDE3A 3839/4885GSK3B 2241/4885 |
| US-20160130247-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-10023543-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
| US-20160152595-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | PDE3B 1440/4885PDE3A 1166/4885GSK3B 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.